Advice

following a full submission assessed under the end of life process:

cabozantinib (Cabometyx®) is not recommended for use within NHSScotland.

Indication under review: advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk.

In a phase II study, in treatment-naïve adults with advanced RCC with intermediate or poor risk as defined by the IMDC risk group categories, cabozantinib was superior to another tyrosine kinase inhibitor for progression free survival.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
cabozantinib (Cabometyx)
SMC ID:
SMC2095
Indication:
Treatment of advanced renal cell carcinoma in treatment-naïve adults with intermediate or poor risk per IMDC criteria.
Pharmaceutical company
Ipsen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Not recommended
Date advice published:
08 October 2018